Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors

Helge R. Brekke, Matthias Kolberg, Rolf Inge Skotheim, Kirsten Sundby Hall, Bodil Bjerkehagen, Bjorn Risberg, Henryk A. Domanski, Nils Mandahl, Knut Liestøl, Sigbjorn Smeland, Havard Danielsen, Fredrik Mertens, Ragnhild Lothe

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The purpose of this study was to identify new prognostic biomarkers with clinical impact in malignant peripheral nerve sheath tumor (MPNST), a highly aggressive malignancy for which no consensus therapy exists besides surgery. We have used tissue microarrays (TMAs) to assess in situ expression of 14 cell-cycle-regulating proteins in 64 well-characterized MPNST patients: 36 sporadic and 28 with neurofibromatosis type 1 (NF1). We developed a new software application for evaluation and logistics of the TMA images and performed a literature survey of cell cycle proteins in MPNST. For NF1-associated patients, there was a clear association between nuclear expression of p53 and poor survival (p = 0.004). Among the other proteins analyzed, we also found significant associations between survival and clinical variables, but none were as strong as that for p53. For the total series of MPNSTs, p53 was shown to be an independent predictor of survival, and patients without remission, with tumor size larger than 8 cm, and with positive p53 expression had a 60 times greater risk of dying within the first 5 years compared with the remaining patients (p = 0.000002). This is the most comprehensive study of in situ protein expression in MPNST so far, and expressed p53 was found to be a strong surrogate marker for outcome. Patients in complete remission with a primary p53-positive MPNST diagnosis may be considered in a high-risk subgroup and candidates for adjuvant treatment.

Original languageEnglish (US)
Pages (from-to)514-528
Number of pages15
JournalNeuro-oncology
Volume11
Issue number5
DOIs
StatePublished - Oct 1 2009

Fingerprint

Neurilemmoma
Survival
Cell Cycle Proteins
Neurofibromatosis 1
Biomarkers
Neoplasms
Proteins
Software
Therapeutics

Keywords

  • Cyclin D1
  • MPNST
  • NF1
  • Neurofibroma
  • p53

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors. / Brekke, Helge R.; Kolberg, Matthias; Skotheim, Rolf Inge; Hall, Kirsten Sundby; Bjerkehagen, Bodil; Risberg, Bjorn; Domanski, Henryk A.; Mandahl, Nils; Liestøl, Knut; Smeland, Sigbjorn; Danielsen, Havard; Mertens, Fredrik; Lothe, Ragnhild.

In: Neuro-oncology, Vol. 11, No. 5, 01.10.2009, p. 514-528.

Research output: Contribution to journalArticle

@article{62ad420a9d2b4c0dbecac49385f2841b,
title = "Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors",
abstract = "The purpose of this study was to identify new prognostic biomarkers with clinical impact in malignant peripheral nerve sheath tumor (MPNST), a highly aggressive malignancy for which no consensus therapy exists besides surgery. We have used tissue microarrays (TMAs) to assess in situ expression of 14 cell-cycle-regulating proteins in 64 well-characterized MPNST patients: 36 sporadic and 28 with neurofibromatosis type 1 (NF1). We developed a new software application for evaluation and logistics of the TMA images and performed a literature survey of cell cycle proteins in MPNST. For NF1-associated patients, there was a clear association between nuclear expression of p53 and poor survival (p = 0.004). Among the other proteins analyzed, we also found significant associations between survival and clinical variables, but none were as strong as that for p53. For the total series of MPNSTs, p53 was shown to be an independent predictor of survival, and patients without remission, with tumor size larger than 8 cm, and with positive p53 expression had a 60 times greater risk of dying within the first 5 years compared with the remaining patients (p = 0.000002). This is the most comprehensive study of in situ protein expression in MPNST so far, and expressed p53 was found to be a strong surrogate marker for outcome. Patients in complete remission with a primary p53-positive MPNST diagnosis may be considered in a high-risk subgroup and candidates for adjuvant treatment.",
keywords = "Cyclin D1, MPNST, NF1, Neurofibroma, p53",
author = "Brekke, {Helge R.} and Matthias Kolberg and Skotheim, {Rolf Inge} and Hall, {Kirsten Sundby} and Bodil Bjerkehagen and Bjorn Risberg and Domanski, {Henryk A.} and Nils Mandahl and Knut Liest{\o}l and Sigbjorn Smeland and Havard Danielsen and Fredrik Mertens and Ragnhild Lothe",
year = "2009",
month = "10",
day = "1",
doi = "10.1215/15228517-2008-127",
language = "English (US)",
volume = "11",
pages = "514--528",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors

AU - Brekke, Helge R.

AU - Kolberg, Matthias

AU - Skotheim, Rolf Inge

AU - Hall, Kirsten Sundby

AU - Bjerkehagen, Bodil

AU - Risberg, Bjorn

AU - Domanski, Henryk A.

AU - Mandahl, Nils

AU - Liestøl, Knut

AU - Smeland, Sigbjorn

AU - Danielsen, Havard

AU - Mertens, Fredrik

AU - Lothe, Ragnhild

PY - 2009/10/1

Y1 - 2009/10/1

N2 - The purpose of this study was to identify new prognostic biomarkers with clinical impact in malignant peripheral nerve sheath tumor (MPNST), a highly aggressive malignancy for which no consensus therapy exists besides surgery. We have used tissue microarrays (TMAs) to assess in situ expression of 14 cell-cycle-regulating proteins in 64 well-characterized MPNST patients: 36 sporadic and 28 with neurofibromatosis type 1 (NF1). We developed a new software application for evaluation and logistics of the TMA images and performed a literature survey of cell cycle proteins in MPNST. For NF1-associated patients, there was a clear association between nuclear expression of p53 and poor survival (p = 0.004). Among the other proteins analyzed, we also found significant associations between survival and clinical variables, but none were as strong as that for p53. For the total series of MPNSTs, p53 was shown to be an independent predictor of survival, and patients without remission, with tumor size larger than 8 cm, and with positive p53 expression had a 60 times greater risk of dying within the first 5 years compared with the remaining patients (p = 0.000002). This is the most comprehensive study of in situ protein expression in MPNST so far, and expressed p53 was found to be a strong surrogate marker for outcome. Patients in complete remission with a primary p53-positive MPNST diagnosis may be considered in a high-risk subgroup and candidates for adjuvant treatment.

AB - The purpose of this study was to identify new prognostic biomarkers with clinical impact in malignant peripheral nerve sheath tumor (MPNST), a highly aggressive malignancy for which no consensus therapy exists besides surgery. We have used tissue microarrays (TMAs) to assess in situ expression of 14 cell-cycle-regulating proteins in 64 well-characterized MPNST patients: 36 sporadic and 28 with neurofibromatosis type 1 (NF1). We developed a new software application for evaluation and logistics of the TMA images and performed a literature survey of cell cycle proteins in MPNST. For NF1-associated patients, there was a clear association between nuclear expression of p53 and poor survival (p = 0.004). Among the other proteins analyzed, we also found significant associations between survival and clinical variables, but none were as strong as that for p53. For the total series of MPNSTs, p53 was shown to be an independent predictor of survival, and patients without remission, with tumor size larger than 8 cm, and with positive p53 expression had a 60 times greater risk of dying within the first 5 years compared with the remaining patients (p = 0.000002). This is the most comprehensive study of in situ protein expression in MPNST so far, and expressed p53 was found to be a strong surrogate marker for outcome. Patients in complete remission with a primary p53-positive MPNST diagnosis may be considered in a high-risk subgroup and candidates for adjuvant treatment.

KW - Cyclin D1

KW - MPNST

KW - NF1

KW - Neurofibroma

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=70349628640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349628640&partnerID=8YFLogxK

U2 - 10.1215/15228517-2008-127

DO - 10.1215/15228517-2008-127

M3 - Article

C2 - 19182148

AN - SCOPUS:70349628640

VL - 11

SP - 514

EP - 528

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 5

ER -